The likes of GlaxoSmithKline, Lundbeck and Neurim Pharmaceuticals turn to the team at Gowling WLG for assistance with issues spanning patent disputes, IP portfolio management, joint ventures, M&A, and commercial agreements. The unit is also active across digital health and well-placed to assist funders and operators of care homes and senior living facilities with a range of issues. Jenny Davies co-heads the practice alongside Robert Breedon, who divides his time between Birmingham and London. Davies’ practice spans patent litigation and strategic collaborations, while Breedon frequently leads on large healthcare projects. Paul Inman has a proven track record in multi-jurisdictional patent litigation. Patrick Duxbury‘s varied caseload includes global collaborations and co-commercialisation deals. Huw Evans’ busy portfolio of work includes patent entitlement cases in the French and Spanish Courts. Luke Kempton’s scientific expertise is particularly prized by Japanese companies seeking assistance with drug acquisition, collaboration and licensing deals. Mathilda Davidson specialises in transactional IP matters, while patent expert Christopher Freeth has notable experience with Arrow declarations.
Legal 500 Editorial commentary
Key clients
- BioNTech
- Gyrus Capital
- Neurim Pharmaceuticals
- European Pharmaceutical Company
- AstraZeneca
- Eisai
- Bial Portela
- Katholieke Universiteit Leuven
- GlaxoSmithKline
- Apposite Capital
- Sosei Heptares
- Achilles Therapeutics
- Levicept
- Fresenius Medical Care Renal Services Limited
- Getinge Group (includes ArjoHuntleigh UK, Arjo Ltd Med AB, Arjo Med Aktiebolag, Altrax Group, Getinge Infection Control AB, Getinge UK)
- Guy's & St Thomas' NHS Foundation Trust
- Montreux Healthcare Fixed Yield Fund (inc. Huntercombe Group)
- NHS Birmingham and Solihull Mental Health NHS Foundation Trust
- Oxford BioTherapeutics
- Immedica Pharma AB
- Lundbeck
- Arjo
- LRE Medical
- Corcym
- Millbrook
- Emed
- Chroma Therapeutics
Work highlights
- Advised long-standing client AstraZeneca on a collaboration and license agreement with biopharmaceutical company Quell Therapeutics, in relation to the development and manufacturing of cell therapies.
- Advised BioNTech on their collaboration with the UK Government to accelerate personalised mRNA immunotherapy clinic trails providing personalised cancer therapies for up to 10,000 patients by 2030.
- Acting for Neurim Pharmaceuticals in a series of fast-paced and unusual disputes with Viatris, involving a series of procedurally complicated events in the dispute over a patent for Circadin.
Lawyers
Hall of Fame
The lawyers at the very top of the profession, widely known and respected by peers and clients for their longstanding involvement in market-leading work.
Practice head
The lawyer(s) leading their teams.
Jenny Davies, Robert Breedon